Brokerages Set Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) PT at $3.23

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have been assigned an average rating of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $3.2250.

A number of research firms have issued reports on LXRX. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a report on Tuesday, September 2nd. Citigroup increased their target price on Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the stock a “buy” rating in a report on Thursday, August 7th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Compagnie Lombard Odier SCmA grew its position in Lexicon Pharmaceuticals by 200.0% in the second quarter. Compagnie Lombard Odier SCmA now owns 330,000 shares of the biopharmaceutical company’s stock valued at $312,000 after purchasing an additional 220,000 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of Lexicon Pharmaceuticals by 378.0% in the 4th quarter. Deutsche Bank AG now owns 315,659 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 249,616 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Lexicon Pharmaceuticals in the first quarter valued at approximately $32,000. Northern Trust Corp grew its stake in Lexicon Pharmaceuticals by 14.4% in the fourth quarter. Northern Trust Corp now owns 1,308,651 shares of the biopharmaceutical company’s stock valued at $966,000 after purchasing an additional 164,620 shares in the last quarter. Finally, California State Teachers Retirement System grew its stake in shares of Lexicon Pharmaceuticals by 29.9% in the fourth quarter. California State Teachers Retirement System now owns 195,215 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 44,915 shares in the last quarter. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Price Performance

NASDAQ LXRX opened at $1.34 on Tuesday. The business has a 50 day simple moving average of $1.14 and a 200 day simple moving average of $0.82. Lexicon Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $2.18. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.16 and a current ratio of 4.16. The stock has a market cap of $486.96 million, a price-to-earnings ratio of -4.06 and a beta of 1.26.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.09. Lexicon Pharmaceuticals had a negative net margin of 206.43% and a negative return on equity of 83.63%. The company had revenue of $28.87 million during the quarter, compared to the consensus estimate of $4.87 million. Analysts anticipate that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.